{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:58Z","timestamp":1787002798940,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016669","name":"The Sj\u00f6berg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1519Pj"],"award-info":[{"award-number":["21 1519Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-02221"],"award-info":[{"award-number":["2023-02221"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Oncolytic adenovirus has been widely evaluated as a cancer treatment agent with tolerable toxicity profile. We have recently developed a new oncolytic adenovirus Adf35(OGN) with two immunostimulatory transgenes alpha-1,3-galactosyltransferase (\n                    <jats:italic>GGTA1<\/jats:italic>\n                    ) from\n                    <jats:italic>Sus scrofa<\/jats:italic>\n                    and neutrophil-activating protein (NAP) from\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    . Adf35(OGN) can kill tumor cells and trigger a strong immune response against tumor antigens. Here, we report the toxicity and biodistribution of Adf35(OGN) in Syrian hamster and GGTA1-knockout mouse. The virus was delivered subcutaneously in na\u00efve hamsters and intratumorally in\n                    <jats:italic>GGTA1-<\/jats:italic>\n                    knockout mouse in multiple doses at dosages of 1\u20135\u2009\u00d7\u200910\n                    <jats:sup>11<\/jats:sup>\n                    viral particles (VP)\/kg. The virus did not replicate in any tissues, evidenced as low or no viral copies detected by qPCR. The virus was also found at low levels in biofluids (saliva, urine, and feces), indicating that spread to the environment is low with a low risk of secondary infections via shedding. The virus did not cause any biochemical, hematological, or histopathological alterations. In summary, Adf35(OGN) has a good safety profile in these animal models and these results support future clinical evaluation for Adf35(OGN).\n                  <\/jats:p>","DOI":"10.1038\/s41417-025-00875-y","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:24:49Z","timestamp":1739273089000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biodistribution and toxicity evaluation of oncolytic adenovirus Adf35(OGN) in Syrian hamster and mouse"],"prefix":"10.1038","volume":"32","author":[{"given":"Erik","family":"Yngve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-0351","authenticated-orcid":false,"given":"Di","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"875_CR1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki O, dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13:84.","journal-title":"J Hematol Oncol"},{"key":"875_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer. 2019;7:145.","journal-title":"J Immunother Cancer"},{"key":"875_CR3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","volume":"9","author":"T Reid","year":"2002","unstructured":"Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002;9:979\u201386.","journal-title":"Cancer Gene Ther"},{"key":"875_CR4","doi-asserted-by":"crossref","unstructured":"Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6348630\/. Accessed 3 Mar 2024.","DOI":"10.1186\/s40425-019-0510-7"},{"key":"875_CR5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda M, Moreno R, Gil-Martin M, Cascall\u00f2 M, de Olza MO, Cuadra C, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019. https:\/\/www.liebertpub.com\/doi\/10.1089\/hum.2018.107. Accessed 3 Mar 2024.","DOI":"10.1089\/hum.2018.107"},{"key":"875_CR6","doi-asserted-by":"crossref","unstructured":"Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2\u201312.","DOI":"10.1038\/sj.onc.1203251"},{"key":"875_CR7","doi-asserted-by":"crossref","first-page":"17755","DOI":"10.1016\/S0021-9258(19)77900-9","volume":"263","author":"U Galili","year":"1988","unstructured":"Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and old world monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 1988;263:17755\u201362.","journal-title":"J Biol Chem"},{"key":"875_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12110","volume":"140","author":"U Galili","year":"2013","unstructured":"Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology. 2013;140:1\u201311.","journal-title":"Immunology"},{"key":"875_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.imlet.2015.02.001","volume":"164","author":"M Hamanova","year":"2015","unstructured":"Hamanova M, Chmelikova M, Nentwich I, Thon V, Lokaj J. Anti-Gal IgM, IgA and IgG natural antibodies in childhood. Immunol Lett. 2015;164:40\u20133.","journal-title":"Immunol Lett"},{"key":"875_CR10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/mt.2013.153","volume":"21","author":"M Ramachandran","year":"2013","unstructured":"Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther. 2013;21:2008\u201318.","journal-title":"Mol Ther"},{"key":"875_CR11","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4049\/jimmunol.1400339","volume":"193","author":"M Ramachandran","year":"2014","unstructured":"Ramachandran M, Jin C, Yu D, Eriksson F, Essand M. Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol. 2014;193:2287\u201396.","journal-title":"J Immunol"},{"key":"875_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-018-0350-x","volume":"6","author":"J Lei","year":"2018","unstructured":"Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, et al. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells. J Immunother Cancer. 2018;6:55.","journal-title":"J Immunother Cancer"},{"key":"875_CR13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/hum.2007.017","volume":"18","author":"S Bortolanza","year":"2007","unstructured":"Bortolanza S, Alzuguren P, Bu\u00f1uales M, Qian C, Prieto J, Hernandez-Alcoceba R. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther. 2007;18:681\u201390.","journal-title":"Hum Gene Ther"},{"key":"875_CR14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","volume":"66","author":"MA Thomas","year":"2006","unstructured":"Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006;66:1270\u20136.","journal-title":"Cancer Res"},{"key":"875_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00007890-199601150-00004","volume":"61","author":"RG Tearle","year":"1996","unstructured":"Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJW, et al. The \u03b1-1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation. 1996;61:13.","journal-title":"Transplantation"},{"key":"875_CR16","unstructured":"Posit [Internet]. [cited 2024 Sep 27]. Posit. Available from: https:\/\/www.posit.co\/"},{"key":"875_CR17","doi-asserted-by":"crossref","first-page":"e0182715","DOI":"10.1371\/journal.pone.0182715","volume":"12","author":"L Kuryk","year":"2017","unstructured":"Kuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Lev\u00e4lampi O, et al. Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102\u2014Support for clinical studies on advanced cancer treatment. PLoS ONE. 2017;12:e0182715.","journal-title":"PLoS ONE"},{"key":"875_CR18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cells10020246","volume":"10","author":"R Havunen","year":"2021","unstructured":"Havunen R, Kalliokoski R, Siurala M, Sorsa S, Santos JM, Cervera-Carrascon V, et al. Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1. Cells. 2021;10:246.","journal-title":"Cells"},{"key":"875_CR19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/cgt.2008.80","volume":"16","author":"AM Sonabend","year":"2009","unstructured":"Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, Cao D, et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 2009;16:362.","journal-title":"Cancer Gene Ther"},{"key":"875_CR20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/cgt.2009.5","volume":"16","author":"DL Lichtenstein","year":"2009","unstructured":"Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009;16:644\u201354.","journal-title":"Cancer Gene Ther"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00875-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:56:29Z","timestamp":1742964989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00875-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00875-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OK and DY submitted a patent application regarding development of Adf35(OGN). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}